Opemmundi E Ljbope
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Boston Symphony Orchestra Concert Programs, Summer, 2001, Tanglewood
SEMI OIAWA MUSIC DIRECTOR BERNARD HAITINK PRINCIPAL GUEST CONDUCTOR • i DALE CHIHULY INSTALLATIONS AND SCULPTURE / "^ik \ *t HOLSTEN GALLERIES CONTEMPORARY GLASS SCULPTURE ELM STREET, STOCKBRIDGE, MA 01262 . ( 41 3.298.3044 www. holstenga I leries * Save up to 70% off retail everyday! Allen-Edmoi. Nick Hilton C Baccarat Brooks Brothers msSPiSNEff3svS^:-A Coach ' 1 'Jv Cole-Haan v2^o im&. Crabtree & Evelyn OB^ Dansk Dockers Outlet by Designs Escada Garnet Hill Giorgio Armani .*, . >; General Store Godiva Chocolatier Hickey-Freeman/ "' ft & */ Bobby Jones '.-[ J. Crew At Historic Manch Johnston & Murphy Jones New York Levi's Outlet by Designs Manchester Lion's Share Bakery Maidenform Designer Outlets Mikasa Movado Visit us online at stervermo OshKosh B'Gosh Overland iMrt Peruvian Connection Polo/Ralph Lauren Seiko The Company Store Timberland Tumi/Kipling Versace Company Store Yves Delorme JUh** ! for Palais Royal Phone (800) 955 SHOP WS »'" A *Wtev : s-:s. 54 <M 5 "J* "^^SShfcjiy ORIGINS GAUCftV formerly TRIBAL ARTS GALLERY, NYC Ceremonial and modern sculpture for new and advanced collectors Open 7 Days 36 Main St. POB 905 413-298-0002 Stockbridge, MA 01262 Seiji Ozawa, Music Director Ray and Maria Stata Music Directorship Bernard Haitink, Principal Guest Conductor One Hundred and Twentieth Season, 2000-2001 SYMPHONY HALL CENTENNIAL SEASON Trustees of the Boston Symphony Orchestra, Inc. Peter A. Brooke, Chairman Dr. Nicholas T. Zervas, President Julian Cohen, Vice-Chairman Harvey Chet Krentzman, Vice-Chairman Deborah B. Davis, Vice-Chairman Vincent M. O'Reilly, Treasurer Nina L. Doggett, Vice-Chairman Ray Stata, Vice-Chairman Harlan E. Anderson John F. Cogan, Jr. Edna S. -
Remote Control Code List
Remote Control Code List MDB1.3_01 Contents English . 3 Čeština . 4 Deutsch . 5 Suomi . 6 Italiano . 7. Nederlands . 8 Русский . .9 Slovenčina . 10 Svenska . 11 TV Code List . 12 DVD Code List . 25 VCR Code List . 31 Audio & AUX Code List . 36 2 English Remote Control Code List Using the Universal Remote Control 1. Select the mode(PVR, TV, DVD, AUDIO) you want to set by pressing the corresponding button on the remote control. The button will blink once. 2. Keep pressing the button for 3 seconds until the button lights on. 3. Enter the 3-digit code. Every time a number is entered, the button will blink. When the third digit is entered, the button will blink twice. 4. If a valid 3-digit code is entered, the product will power off. 5. Press the OK button and the mode button will blink three times. The setup is complete. 6. If the product does not power off, repeat the instruction from 3 to 5. Note: • When no code is entered for one minute the universal setting mode will switch to normal mode. • Try several setting codes and select the code that has the most functions. 3 Čeština Seznam ovládacích kódů dálkového ovladače Používání univerzálního dálkového ovladače 1. Vyberte režim (PVR, TV, DVD, AUDIO), který chcete nastavit, stisknutím odpovídajícího tlačítka na dálkovém ovladači. Tlačítko jednou blikne. 2. Stiskněte tlačítko na 3 sekundy, dokud se nerozsvítí. 3. Zadejte třímístný kód. Při každém zadání čísla tlačítko blikne. Po zadání třetího čísla tlačítko blikne dvakrát. 4. Po zadání platného třímístného kódu se přístroj vypne. -
Universal Remote Code Book
Universal Remote Code Book www.hestia-france.com TV CENTURION 0051 0169 CENTURY 0000 A CGE 0129 0047 0131 0043 ACER 1484 CIMLINE 0009 0028 ACME 0013 CITY 0009 ADA 0008 CLARIVOX 0169 0037 ADC 0012 0008 CLATRONIC 0009 0011 0051 0002 0083 ADMIRAL 0019 0108 0002 0001 0047 0003 0129 0030 0043 0000 COMBITECH 0248 ADYSON 0003 CONCORDE 0009 AGAZI 0002 CONDOR 0198 0051 0083 0003 0245 AGB 0123 CONRAC 0038 1395 AIKO 0003 0009 0004 CONTEC 0003 0009 0027 0030 0029 AIWA 0184 0248 0291 CONTINENTAL EDISON 0022 0111 0036 0045 0126 AKAI 1410 0011 0086 0009 0068 0139 0046 0004 0006 0008 0051 0061 COSMEL 0009 0088 0169 0200 0133 0141 CPRTEC 0156 0069 CROSLEY 0129 0131 0000 0043 AKIBA 0011 CROWN 0009 0169 0083 0047 0051 AKURA 0169 0074 0002 0009 0011 0245 0121 0043 0071 CS ELECTRONICS 0011 0129 0003 ALBA 0028 0027 0009 0011 0003 CTC 0129 0068 0083 0169 0047 0245 CTC CLATRONIC 0014 0248 0162 0062 CYBERCOM 0177 0038 0171 0002 0009 ALBIRAL 0037 0206 0205 0207 0208 0210 ALKOS 0164 0169 0042 0044 0127 0047 ALLORGAN 0157 0026 0061 0063 0067 0068 0103 ALLSTAR 0051 0107 0115 0154 0168 0185 ALTUS 0042 0228 0209 0343 0924 0933 AMPLIVISION 0003 0248 0291 AMSTRAD 0011 0009 0068 0074 0002 CYBERMAXX 0177 0038 0171 0002 0009 0108 0071 0069 0030 0123 0206 0200 0205 0207 0208 0013 0210 0211 0169 0015 0042 ANAM 0009 0065 0109 0044 0047 0048 0049 0061 ANGLO 0009 0063 0067 0068 0087 0103 ANITECH 0009 0002 0043 0109 0107 0115 0127 0154 0155 ANSONIC 0009 0014 0168 0170 0185 0228 0229 AOC 0134 0209 0218 1005 0894 0343 ARC EN CIEL 0126 0045 0139 0924 0933 0248 0291 ARCAM 0003 CYBERTRON -
Fisher & Paykel Appliances Holdings Limited
FISHER & PAYKEL APPLIANCES HOLDINGS LIMITED TARGET COMPANY STATEMENT — IN RELATION TO A TAKEOVER OFFER BY HAIER NEW ZEALAND INVESTMENT HOLDING COMPANY LIMITED — 4 OCTOBER 2012 For personal use only For personal use only COVER: PHASE 7 DISHDRAWER TM DISHWASHER FISHER & PAYKEL APPLIANCES HOLDINGS LIMITED TARGET COMPANY STATEMENT CHAIRMAN’S LETTER 03 TARGET COMPANY STATEMENT (TAKEOVERS CODE DISCLOSURES) 07 SCHEDULE 1 — 4 25 For personal use only APPENDIX: INDEPENDENT ADVISER’S REPORT 37 CHAIRMAN’S LETTER For personal use only CHAIRMAN’S LETTER P3 Dear Shareholder Haier New Zealand Investment Holding Company Limited (“Haier”) has offered $1.20 per share to buy your shares in Fisher & Paykel Appliances Holdings Limited (“FPA”) by means of a formal takeover offer (the Offer“ ”). •• INDEPENDENT DIRECTORS RECOMMEND DO NOT ACCEPT HAIER’S OFFER •• The independent directors of FPA (Dr Keith Turner, Mr Philip Lough, Ms Lynley Marshall and Mr Bill Roest) (the “Independent Directors”) unanimously recommend that shareholders do not accept the Offer from Haier. In making their recommendation, the Independent Directors have carefully considered a full range of expert advice available to them. Therefore you should take no action. The principal reasons for recommending that shareholders do not accept are: _ Having regard to a full range of expert advice now available to the Independent Directors (including the Independent Adviser’s valuation range of $1.28 to $1.57 per FPA Share), the Independent Directors consider that the Offer of $1.20 per FPA Share does not adequately reflect their view of the value of FPA based on their confidence in the strategic direction of the Company; and _ FPA is in a strong financial position and, as the Independent Adviser notes, FPA is at a “relatively early stage of implementation of the company’s comprehensive rebuilding strategy”. -
Good Design 2012 Awarded Product Designs and Graphics and Packaging
GOOD DESIGN 2012 AWARDED PRODUCT DESIGNS AND GRAPHICS AND PACKAGING THE CHICAGO ATHENAEUM: MUSEUM OF ARCHITECTURE AND DESIGN THE EUROPEAN CENTRE FOR ARCHITECTURE ART DESIGN AND URBAN STUDIES ELECTRONICS 2012 JBL Professional VTX Line Array, 2010-2012 Designers: Myk Lum, Daniel Yoon, Joe Morin, William Yeh, and Ken Sugimoto, LDA LLC., Irvine, California, USA Manufacturer: JBL Professional, Northridge, California, USA Jabra STONE 2 Wireless Bluetooth® Headsets, 2010 Designers: Johan Birger, Johan Birger AB., Malmo, Sweden Manufacturer: GN Store Nord A/S., Ballerup, Denmark Jabra SPORT Wireless Bluetooth® Headsets, 2011 Designers: Johan Birger, Johan Birger AB., Malmo, Sweden Manufacturer: GN Store Nord A/S., Ballerup, Denmark Dell XPS 13 Ultrabook, 2012 Designers: Dell Inc., Round Rock, Texas, USA Manufacturer: Dell Inc., Round Rock, Texas, USA Hewlett-Packard webcam HD 5210, 2010-2011 Designers: BMW Group Designworks USA, Newbury Park, California, USA Manufacturer: Hewlett-Packard Co., Palo Alto, California, USA Siragon AIO 9000 Series All-in-One Computer, 2010-2011 Designers: BMW Group Designworks USA, Newbury Park, California, USA Manufacturer: Siragon C.A., Valencia, Venezuela Thermaltake Level 10 M Mouse, 2012 Designers: BMW Group Designworks USA, Newbury Park, California, USA Manufacturer: Thermaltake Technology Co., Ltd., Taipei City, Taiwan Sennheiser S2 Digital Aviation Headset, 2011 Designers: BMW Group Designworks USA, Newbury Park, California, USA Manufacturer: Sennheiser Electronic GmbH & Co. KG., Wedemark, Germany Etón FRX Field Radio Line, 2011 Designers: Dan Harden, Hiro Teranishi, and Sam Benavidez, Whipsaw, Inc., San Jose, California, USA Manufacturer: Etón Corporation, Palo Alto, California, USA Etón Rukus Bluetooth Stereo Line, 2011 Designers: Dan Harden and Kyle Buzzard, Whipsaw, Inc., San Jose, California, USA Manufacturer: Etón Corporation, Palo Alto, California, USA Good Design Awards 2012 Page 1 of 49 December 15, © 1992-2012 The Chicago Athenaeum - Use of this website as stated in our legal statement. -
Coordination Des Syndicats CGT
Coordination des syndicats CGT STRATEGIE DE LA DIRECTION DU GROUPE SANOFI CONSEQUENCES INDUSTRIELLES ET SOCIALES Document d’août 2014 1. Situation économique – Coût du capital p2 2. Evolution des effectifs – Bilan des restructurations majeures p3 3. Stratégie Sanofi 2009-2015 : Désengagement scientifique et industriel en Europe et plus particulièrement en France p4 4. Stratégie de structuration du groupe en entités qui peuvent être cédées, vendues, fermées, échangées. p6 5. Crédit d’impôt – Des aides publiques pour quel usage ? p7 6. Industrie pharmaceutique : des besoins fondamentaux p7 7. Interpellation des élus et du gouvernement p8 1. Situation économique – Coût du capital Première entreprise pharmaceutique française et européenne. Sanofi est issu de la fusion de nombreux laboratoires pharmaceutiques français dont les principaux étaient Roussel Uclaf, Rhône Poulenc, Synthelabo, Sanofi et de l’allemand Hoechst. Sanofi représente 30 à 40% du potentiel national (effectifs, sites, R&D,…) de l’industrie pharmaceutique française dans notre pays. L’avenir du groupe et de ses activités en France conditionne l’avenir de l’industrie pharmaceutique française et constitue un élément incontournable de l’indépendance thérapeutique du pays. Le C.A. de sanofi dans le monde sur 2013 a atteint 33 milliards € et devrait se situer à un niveau légèrement supérieur en 2014. Plusieurs médicaments de référence étant aujourd’hui tombés dans le domaine public, le chiffre d’affaires repart à la hausse. Le résultat net des activités a été de 6,8 milliards € en 2013 et les projections sur 2014 laissent envisager une progression de 5% de celui-ci. La rentabilité est estimée par les économistes parmi les meilleures de l’industrie pharmaceutique dans le monde. -
City of Edinburgh Hotel Development Schedule 2019
City of Edinburgh Hotel Development Schedule 2019 Planning, City of Edinburgh Council, March 2020 Contents Commentary Graph 1 - Hotel developments in Edinburgh 2019 Graph 2 - Historic trends Summary of hotel developments (no. of rooms) by area Table 1 - Schedule of developments completed in 2019 Table 2 - Schedule of developments under construction at year end 2019 Table 3 - Schedule of developments that gained planning consent in 2019 Table 3a - Schedule of other developments with planning consent at year end 2019 Table 4 - Schedule of developments awaiting planning determination at year end 2019 Table 5 - Schedule of closures occurring in 2019 Explanatory notes Whilst reasonable efforts have been made to verify the information in this report, the City of Edinburgh Council are unable to provide an assurance as to the accuracy, currency or comprehensiveness of tables and commentary. Users should undertake their own checks before using the data in this report as an input to policy or investment decisions. This schedule has been prepared by Planning, City of Edinburgh Council. contact: Simon Antrobus ([email protected], 0131-469-3597) Commentary Development summary Market analysis This is the thirteenth hotel schedule to be produced by the City of Edinburgh Council. It has been developed in response to the The hotel sector in Edinburgh continues to display strong signs of growing demand for hotel space in the city and the consequent growth. There was planning consent for 1,530 rooms at the end of increase in hotel planning applications and developments. The 2019. Occupancy levels for the year decreased slightly from 83.6% schedule details completions, properties under construction, to 82.9%. -
Baccarat Hotel & Residences New York
Hospitality Awards Submission Best Innovation In Concept Prepared by HL Group Table of Contents • Summary • Presentation Document • Representative Information • Hotel Photography Summary Baccarat has long been a symbol of elegance in the lives & homes of kings, queens, sultans, tsars, moguls and rock stars. Intimately entwined with the fine art of living, its translation from luxury product to sumptuous hotel, from glittering objet to gracious lifestyle, is a natural evolution of the brand’s unique culture of craft and impeccable provenance. Baccarat Hotel & Residences New York is industry titan Barry Sternlicht’s stunning return to the hospitality space. Opened on March 18, 2015, Baccarat Hotel & Residences New York was an instant classic, offering French glamour and design through the lens of New York City. As the first hotel and global flagship for Baccarat Hotels & Resorts, Baccarat Hotel & Residences New York is a thoughtful and elegant homage to the 250 year-old heritage Baccarat crystal brand. The property boasts 114 elegantly appointed guest rooms and suites, two opulent lobby salons, a 60-foot barrel-vaulted bar, the first Spa de La Mer in the world and a new modern French restaurant, Chevalier, overseen by Michelin-starred Executive Chef Shea Gallante. Legendary New York restaurateur Charles Masson curated the style and service for Chevalier during launch. Paris-based interior design firm Gilles & Boissier led the creation of the hotel’s interiors, which combine Baccarat’s French classic aesthetics with a fanciful modern sensibility. Celebrated decorator Stephen Sills created the elegant setting for the street-level Chevalier restaurant and Skidmore, Owings & Merrill served as architects for the 50-story tower. -
List of Green Hotels and Event Venues
BCA List of Green Hotels S/N Project Name Awards Postal Code 1 Amara Sanctuary Resort Sentosa Platinum 099394 2 Carlton City Hotel Singapore Platinum 078862 3 Copthorne King's Hotel Platinum 169632 4Courtyard Singapore Novena Platinum 329568 5 Furama City Centre Platinum 059804 6 Furama RiverFront, Singapore Platinum 169633 7 Genting Hotel Jurong Platinum 608516 8 Grand Copthorne Waterfront Hotel Platinum 169663 9 Grand Park City Hall Hotel Platinum 179809 10 Great World Serviced Apartments Platinum 239404 11 Holiday Inn Express (88 East Coast Road) Platinum 423371 12 Holiday Inn Express Singapore Orchard Road Platinum 229921 13 Holiday Inn Express, Clarke Quay Platinum 059573 14 Hotel Boss Platinum 199020 15 Hotel Indigo Singapore Katong Platinum 428788 16 Hotel Jen Orchardgateway Platinum 238858 17 ibis Singapore Novena Platinum 329543 18 JW Marriott Hotel Singapore South Beach Platinum 189763 19 King's Centre Platinum 169662 20 M Social Hotel Platinum 238259 21 Marina Bay Sands Platinum 018956 22 One Farrer Hotel & Spa Platinum 217562 23 PARKROYAL on Kitchener Platinum 208533 24 PARKROYAL on Pickering Platinum 058289 25 Sheraton Towers Singapore Hotel Platinum 228230 26 Sofitel Singapore City Centre (Tanjong Pagar Centre) Platinum 078885 27 Sofitel So Singapore Platinum 068876 28 Swissotel Merchant Court, Singapore Platinum 058281 29 The Singapore EDITION hotel (Boulevard 88) Platinum 248651 30 Treetops Executive Residences Platinum 258355 31 Village Hotel Albert Court Platinum 189971 32 W Singapore Sentosa Cove Platinum 098374 PLUS -
Ce Que Sanofi Dit De La Politique Industrielle Française
Ce que Sanofi dit de la politique industrielle française mediapart.fr/journal/economie/030221/ce-que-sanofi-dit-de-la-politique-industrielle-francaise Martine Orange, Mediapart, 3 février 2021 Les salariés de Sanofi ont beau essayer de chercher des explications, ils ne comprennent pas. Ou plutôt ils ne comprennent que trop bien la conduite du groupe pharmaceutique. Après le revers de sa stratégie dans l’élaboration d’un vaccin contre le Covid-19, repoussé désormais au mieux à la fin de l’année, tout aurait dû pousser la direction de Sanofi à s’interroger sur la pertinence de ses choix, sur la place laissée à la recherche jugée comme essentielle. Mais rien ne s’est passé. Le 28 janvier, la direction de Sanofi Recherche et Développement en France a confirmé à l’occasion d’un comité social d’entreprise (CSE) la suppression de 364 emplois en France, une mesure qui vise particulièrement l’unité de Strasbourg appelée à être transférée en région parisienne. Ce plan s’inscrit dans un programme plus large annoncé en juillet 2020. Le groupe entend supprimer 1 700 emplois en Europe dont un millier en France sur trois ans. « Mais ce n’est qu’une partie du projet Pluton, prévient Jean-Louis Perrin, délégué CGT à Montpellier. Sanofi est en train de se désindustrialiser. Toute la pharmacie de synthèse est appelée à disparaître dans le groupe. Les sites de Sisteron, Elbeuf, Vertolaye, Brindisi (Italie), Francfort (Allemagne), Haverhill (Royaume-Uni), Újpest (Hongrie) sont destinés à sortir du groupe. Au total, cela représente 3 500 emplois. » Centre de distribution de Sanofi à Val-de-Reuil. -
Fusiones 20De 20Labo
"Cuando los grandes se hacen gigantes" Fusiones de Laboratorios 1 INDICE PRÓLOGO……………………………………………………………………………...…….. 3 INTRODUCCIÓN: FUSIONES Y ADQUISICIONES…………………………………..….. 4 INVESTIGACIÓN Y DESARROLLO………………………………………………………. 5 LA INDUSTRIA FARMACEUTICA………………………………………………………. 16 FUSIÓN SANOFI – AVENTIS…………………………………………………………...… 20 FUSIÓN BAYER – SCHERING……………………………………………………………. 26 FUSIÓN PFIZER – WYETH……………………………………………………………….. 30 FUSIÓN MERCK & CO. – SCHERING PLOUGH…………………………………..……. 31 FUSIÓN ROCHE – GENENTECH………………………………………………………… 34 MERCADOS REGIONALES………………………………………………………….…… 40 LA INDUSTRIA FARMACÉUTICA EN LA ARGENTINA……………………...………. 42 CONCLUSIÓN……………………………………………………………………………… 49 2 PRÓLOGO Es un verdadero privilegio que hayan pensado en mí para prologar este interesante trabajo relacionado con la formación profesional de estos inquietos alumnos de la Carrera de Agentes de Propaganda Médica. Grato además, pues recrea mi participación activa en el mundo de la Industria Farmacéutica, en calidad de Asesor de la Fuerza de Ventas e Investigador Principal durante varias décadas, período que fue enriquecedor para mí y sumó un importante valor agregado a mi bagaje médico y personal. Entiendo que lo sucedido en los avances científicos y tecnológicos durante los últimos cuarenta años, ha constituido un quiebre en la Historia de la Medicina y, por lo tanto, de la Humanidad. Es por ello que veo con beneplácito que la formación de estos entusiastas jóvenes va de la mano con los cambios de planes y esquemas de estudios de los futuros médicos. -
The Life of the Abortion Pill in the United States
The Life of the Abortion Pill in the United States The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation The Life of the Abortion Pill in the United States (2000 Third Year Paper) Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852153 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA 80 The Life of the Abortion Pill in the United States Julie A. Hogan Eleven years after mifepristone1, the drug that chemically induces abortion and hence coined the abortion pill, was approved for use in France, American women still do not have access to the drug, although women in at least ten other nations do.2 In 1988, Americans thought the Abortion Pill [was] on the Hori- zon.3 In 1993, almost five years later, American women still did not have access to the drug, although many women's hopes were raised by newspaper headlines claiming that the Door May Be Open for [the] Abortion Pill to Be Sold in [the] U.S.4 and newspaper accounts predicting that mifepristone would be available in the United States in 1996.5 In 1996, the headlines reported that the Approval of [the] Abortion Pill by the FDA [was] Likely Soon.6 Yet, mifepristone was still not available in 1999, and newspaper headlines were less optimistic about pre- 1Mifepristone is the generic name for RU-486, the designation given the drug by its French maker, Roussel-Uclaf.